DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for aromatase excess syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAromatase excess syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for aromatase excess syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome P450 family 19 subfamily A member 1 (CYP19A1) — CYP19A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3S79 · 2.75 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
A 2024 report on a family with aromatase excess syndrome describes four members carrying the same monoallelic 0.3-Mb deletion in 15q21 involving parts of CYP19A1, GLDN and DMXL2. The index patient, an 8-year-old boy, presented with gynecomastia, accelerated growth and bone age; by puberty his estradiol was elevated and testosterone low, gynecomastia progressed and he underwent mastectomy twice. Letrozole was started at age 19 years at low dose, and was associated with increased testicular volume, increased virilisation, and improved physical strength and libido. His brother, diagnosed at age 3 years with accelerated growth and bone age, began letrozole at age 7 years and reached an adult height of 179 cm without developing gynecomastia. His sister, diagnosed at age 6 years with premature thelarche and accelerated growth and bone age, was treated with an oestrogen receptor modulator and a GnRH analogue before letrozole; menarche occurred at 13.5 years and adult height was 158 cm. Their father had early accelerated growth, adult height 171 cm, delayed puberty and no gynecomastia. The authors note phenotypic variability within the family despite the same microdeletion.
Earlier literature confirms that aromatase excess syndrome is a rare autosomal dominant disorder caused by CYP19A1 overexpression from genomic rearrangements, leading to prepubertal or peripubertal gynecomastia in males, bone age advancement, and short adult height, with only a few female patients described. A 2020 review states that aromatase deficiency from biallelic loss-of-function mutations produces virilisation, ovarian cysts, and metabolic symptoms, while aromatase excess syndrome produces the opposite hormonal picture. The 2024 report is the only source providing specific outcomes of aromatase inhibitor treatment in this syndrome.
A 2020 paediatric review of third-generation non-steroidal aromatase inhibitors notes that letrozole and anastrozole have been used in McCune-Albright syndrome, familial male-limited precocious puberty, gynaecomastia, and short stature in adolescent boys, with observed efficacy and safety, but emphasises that drug labels do not show paediatric indications, that risks to liver and kidney function, lipid metabolism, hyperandrogenaemia and bone metabolism exist, and that long-term effects on reproductive system and bone metabolism remain unclear. It states that routine use to improve adult height in short adolescent boys is not recommended and that more clinical evidence for safety and effectiveness in children is needed.
What is still missing: larger case series or controlled trials in aromatase excess syndrome; long-term follow-up data on bone health, fertility, and metabolic outcomes in children and adolescents treated with aromatase inhibitors; and any systematic investigation of optimal dosing, duration, or timing of treatment. The 2024 family report is a single observation, not a trial, and the paediatric review explicitly warns that evidence for safety and effectiveness in children is insufficient.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Reproduction · 2005 · 101 citations · open access
Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women
AbstractBACKGROUND: Aromatase catalyses the conversion of androgens to estrogens and thus variation in the aromatase gene could contribute to female syndromes of androgen excess, such as precocious pubarche (PP) and polycystic ovarian syndrome (PCOS). METHODS: Two groups, one case-control containing girls from Barcelona, Spain with PP (n = 186) or healthy controls (n = 71), and the other a population study of young women from Oxford, UK, who volunteered for a study of normal women's health (n = 109), were genotyped at four aromatase gene haplotype-tag single nucleotide polymorphisms (SNP). Clinical features and hormone concentrations relevant to hyperandrogenism were compared across haplotypes or genotypes. RESULTS: Distributions of aromatase haplotypes (P < 0.0001) and aromatase SNP_50 genotype (P = 0.001) were significantly different between PP girls and Spanish controls. The AGGG haplotype was associated with an odds ratio (95% confidence interval) of 0.5 (0.3-0.9) (P = 0.005) for the presence of PP compared to GAGG. In 84 post-pubertal PP girls, aromatase haplotype was associated with functional ovarian hyperandrogenism (P < 0.05), independently of insulin sensitivity. In the Oxford population, SNP_50 was associated with variation in PCOS symptom score (P = 0.008) and circulating testosterone concentrations (P = 0.02). CONCLUSIONS: This study suggests that common variation at the aromatase gene (and not just rare loss-of-function mutations) is associated with androgen excess in girls and young women.
Current Opinion in Obstetrics & Gynecology · 2009 · 37 citations
Managing the toxicities of the aromatase inhibitors
AbstractPURPOSE OF REVIEW: The aromatase inhibitors are increasingly used as adjuvant therapy in postmenopausal women with hormone receptor positive breast cancer. With additional experience using these agents, unanticipated side effects have become apparent. Women who experience side effects from adjuvant endocrine therapy are the individuals who derive the greatest benefits. Because noncompliance is highest among those who experience side effects, it is important that these symptoms be palliated. RECENT FINDINGS: The symptomatic effects of aromatase inhibitors include: hot flashes, arthralgias, vaginal dryness and dyspareunia. Hot flashes may successfully be treated with either serotonin reuptake inhibitors or gabapentin. Counseling, vaginal moisturizers and lubricants can improve symptoms related to sexual functioning. The mechanism of arthralgias is uncertain and anti-inflammatory agents are seldom effective. Patients who experience severe musculoskeletal discomfort may necessitate switching to another endocrine agent such as tamoxifen. Physicians should be aware of 'silent' side effects. Screening for bone loss and hypercholesterolemia is critical and patients should be treated accordingly. SUMMARY: Patients and physicians should openly discuss the short and long-term side effects of the aromatase inhibitors as many of these symptoms can be managed effectively. By optimizing quality of life on adjuvant endocrine therapy, noncompliance may be minimized.
Endocrine Related Cancer · 2011 · 19 citations · open access
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer
AbstractThe introduction of aromatase inhibitors (AI) has provided more options for adjuvant treatment of postmenopausal women; they are associated with improved disease-free survival, but less commonly with improvements in overall survival. Current evidence suggests that women at high risk of recurrence, especially those with node-positive disease, should receive an AI for 2 years as part of their treatment, but routine prescription of AIs to postmenopausal patients with low-risk disease is not appropriate. Not only the expected benefits but also the specific toxicity of the prescribed hormone therapy, and its cost, should be considered when selecting treatment.
Current Opinion in Endocrine and Metabolic Research · 2020 · 5 citations · open access
Puberty in patients with aromatase disorders
AbstractAromatase encoded by CYP19A1 is a microsomal enzyme that converts androgens to estrogens. CYP19A1 loss-of-function because of biallelic mutations leads to aromatase deficiency, whereas CYP19A1 overexpression because of genomic rearrangements results in aromatase excess syndrome. These aromatase disorders exert various effects on sexual maturation and stature growth during puberty. Specifically, aromatase deficiency is associated with aberrant linear growth, ovarian cysts, metabolic symptoms, and virilization, whereas aromatase excess syndrome causes prepubertal or peripubertal onset gynecomastia and bone age advancement with or without mild hypogonadism. The pubertal phenotypes of aromatase disorders likely reflect the accumulation or deficiency of sex hormones, as well as perturbed gonadotropin secretion.
Frontiers in Endocrinology · 2024 · 3 citations · open access
Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome
AbstractIntroduction Aromatase excess syndrome (AEXS) is a rare, autosomal dominant disorder, characterized by enhanced aromatization of androgens and estrogen excess. In males it is characterized by pre-/peripubertal gynecomastia, hypogonadotropic hypogonadism, advanced bone age and short adult height. Only a few female patients have been described so far. Methods We report on a family with four members with AEXS and present the long-term effects of aromatase inhibitor use in three of them. Genetic analysis showed a monoallelic 0.3-Mb deletion in 15q21, involving parts of CYP19A1 , GLDN and DMXL2 in all four patients with AEXS. Results The index patient (male, 8 years old) presented with gynecomastia and accelerated growth and bone age. With start of puberty, estradiol levels increased, while testosterone levels remained low. Gynecomastia progressed and a mastectomy was performed twice. Presuming AEXS, a therapy with letrozole was initiated at the age of 19 years. Low-dose letrozole treatment was associated with an increase in testicular volume, increase in virilization and improvement in physical strength and libido. His brother (age 3 years) presented with accelerated growth and bone age. Treatment with letrozole, which was started at the age of 7 years, resulted in achieving an adult height of 179 cm and prevented the appearance of gynecomastia. His sister (age 6 years), who presented with premature thelarche and accelerated growth and bone age, was treated with an estrogen receptor modulator and a GnRH analog followed by letrozole treatment. Menarche occurred at age 13.5 years and adult height was 158 cm. Their father had an early, accelerated growth with an adult height of 171 cm, a delayed puberty and no gynecomastia. In vitro studies provided evidence for involvement of aromatase induction in atypical cells and an increased range of potential mechanisms regulating aromatase activity due to the presence of the mutated allele. Discussion In conclusion, we observed a phenotypic variability within family members with AEXS carrying the same CYP19A1 microdeletion. When started early, treatment with letrozole was found to prevent the development of gynecomastia and increase adult height in one patient. In adult life, low-dose letrozole treatment resulted in improved physical strength and libido in the index patient.
[Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics].
AbstractAromatase is the rate-limiting enzyme in estrogen biosynthesis. The third generation aromatase inhibitors (AIs), represented by letrozoleand and anastrozole, can combine with aromatase, effectively reducing the estrogen level in the body. Because of its high efficiency, selectivity and reversibility, it has been used in the treatment of McCune-Albright syndrome, familial male-limited precocious puberty, gynecomastia, and adolescent boy with short stature. The good efficacy and safety of AIs have been observed. However, so far the drug instructions of AIs usually do not show indications for children; there are risks of adverse reactions involving liver and kidney function, lipid metabolism, hyperandrogenemia and bone metabolism; especially the long-term effects on reproductive system and bone metabolism are still not clear. Therefore, it is necessary to prescribe it carefully and follow up closely. It was not recommended that AIs be routinely used to improve adult height of adolescent boy with short stature. And more clinical evidences are needed for the safety and effectiveness of AIs prescribed in pediatrics.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
